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Edited by Veli-Pekka LehtoAbstract To understand signaling by the neuregulin (NRG)
receptor ErbB3/HER3, it is important to know whether ErbB3
forms homodimers upon ligand binding. Previous biophysical
studies suggest that the ErbB3 extracellular region remains
monomeric when bound to NRG. We used a chimeric receptor
approach to address this question in living cells, fusing the
extracellular region of ErbB3 to the kinase-active intracellular
domain of ErbB1. The ErbB3/ErbB1 chimera responded to NRG
only if ErbB2 was co-expressed in the same cells, whereas an
ErbB4/ErbB1 chimera responded without ErbB2. We, therefore,
suggest that ErbB3 is an obligate heterodimerization partner
because of its inability to homodimerize.
 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The epidermal growth factor (EGF) receptor, or ErbB,
family of receptor tyrosine kinases play important roles in
normal embryonic development, and their aberrant signaling is
associated with human cancers [1,2]. There are four members
of the family: the EGF receptor itself (EGFR or ErbB1),
ErbB2 (also known as HER2 or Neu), ErbB3 (HER3) and
ErbB4 (HER4). Each has a large (620 amino acid) extra-
cellular ligand-binding region, a single transmembrane a-helix,
and an intracellular region containing the tyrosine kinase do-
main plus regulatory sequences. ErbB1/EGFR is activated
directly by multiple ligands, which promote homodimerization
and autophosphorylation of the receptor [3]. ErbB4 appears to
be regulated (in part) in a similar manner, but by neuregulins
(NRGs) rather than EGF receptor agonists [4]. By contrast,
ErbB2 has no known direct extracellular ligands, and ErbB3
binds NRGs but appears to have a non-functional tyrosine
kinase domain [5–8].
The ErbB receptors form a network of homo- and hetero-
dimers [1,9]. ErbB2 can only be regulated indirectly, and is
thought to be the preferred heterodimerization partner for
other ErbB receptors [10]. ErbB3, on the other hand, must
associate with an ErbB family member that has an active ty-* Corresponding author. Fax: +1-215-573-4764.
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thought that the NRG-induced ErbB3/ErbB2 heterodimer is
among the most potent mitogenic signaling complexes in the
ErbB network [8,11–13]. However, the molecular mechanism
for activation of ErbB2 and ErbB3 through NRG-induced
hetero-oligomerization is not clear. Whereas other receptor
extracellular regions dimerize upon ligand binding, no study of
the ErbB3 extracellular region has detected dimerization upon
NRG binding [14–17]. The ErbB2 extracellular region also fails
to homodimerize even at very high concentrations [15,18,19].
It is important to know whether or not intact ErbB3 ho-
modimerizes on NRG binding in order to understand how
ErbB2/ErbB3 hetero-oligomers signal. If ErbB3 is truly kinase-
inactive, and ErbB receptor activation involves trans-phos-
phorylation of receptors, it is not clear how ErbB2 can become
either activated or phosphorylated within a simple ErbB2/
ErbB3 heterodimer. This diﬃculty could be resolved if sig-
naling occurs in the context of a higher-order ErbB2/ErbB3
hetero-oligomer, such as a heterotetramer, and it has been
suggested that such heterotetramers might be ‘nucleated’ by
NRG-induced ErbB3 homodimerization [3,20]. To test this
hypothesis in a cellular context, we analyzed signaling by
ErbB3/ErbB1 and ErbB4/ErbB1 chimerae to determine whe-
ther NRGs can promote ErbB3 homodimerization at the cell
surface. Under conditions identical to those that promote ro-
bust activation of the ErbB4 chimera, we ﬁnd that NRGs
cannot induce activation of the ErbB3 chimera. Our ﬁndings
argue that NRG does not promote ErbB3 homodimerization
at the cell surface, and have important implications for un-
derstanding the mechanism of signaling through ErbB3/ErbB2
hetero-oligomers.2. Materials and Methods
2.1. Expression constructs
Full-length human ErbB1 and ErbB2 were subcloned into KpnI/NotI
digested pAc5.1/V5-HisA (Invitrogen Corporation, Carlsbad, CA).
Constructs encoding chimerae with the extracellular region plus
transmembrane domain of either ErbB3 or ErbB4 fused to the entire
cytoplasmic sequence of ErbB1 (ErbB3/ErbB1 or ErbB4/ErbB1) were
generated by four-primer PCR. In ErbB3/ErbB1, the ErbB3 fragment
extends through Trp647. In ErbB4/ErbB1, the ErbB4 fragment extends
through Val675. The ErbB1 fragment begins at Arg645 in both cases.
2.2. Cell culture
Schneider-2 (S2) Drosophila melanogaster cells (Invitrogen) were
grown at 24 C in complete Schneider’s Medium (Sigma–Aldrich, St.
Louis, MO), containing penicillin/streptomycin (50 U ml1/50 lgblished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic representation of ErbB receptors and chimerae.
M.B. Berger et al. / FEBS Letters 569 (2004) 332–336 333ml1), and gentamicin (50 lg/ml) (GibcoBRL, Rockville, MD), sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS) (Hy-
Clone, Logan, UT).
2.3. Stable cell-lines
S2 cells were transfected with 20 lg DNA (19 lg desired expression
construct plus 1 lg pCoHygro selection vector (Invitrogen)) using the
calcium phosphate method (Invitrogen). After approximately 3 weeks
of selection, pools of cells resistant to 300 lg/ml Hygromycin B were
expanded and screened for expression by Western blotting and ﬂow
cytometry. All stably expressing cell-pools were maintained in com-
plete Schneider’s Medium supplemented with 10% FBS and 300 lg/ml
Hygromycin B.
2.4. Antibodies
Western blots were probed with anti-ErbB1 antibody Ab-15, anti-
ErbB2 antibody Ab-8 (NeoMarkers, Freemont, CA), anti-phospho-
MAPKinase antibody 9101 (Cell Signaling Technology, Beverly, MA),
anti-MAPKinase antibodyM5670 (Sigma–Aldrich) and anti-phospho-
tyrosine antibody PY20 (Zymed Laboratories, South San Francisco,
CA). Flow cytometry was performed with R-phycoerythrin (R-PE)-
conjugated anti-EGFR, R-PE-conjugated anti-HER-2/Neu antibodies,
R-PE-conjugated secondary antibodies (rat anti-mouse IgG2aþb and rat
anti-mouse IgG1) (BD Biosciences, Franklin Lakes, NJ), anti-ErbB3
antibody Ab-4, and anti-ErbB4 antibody Ab-1 (NeoMarkers).
2.5. Flow cytometry
For analysis of ErbB1 and ErbB2 expression, cells were incubated
for 30 min on ice with PE-conjugated antibodies, and then diluted to
approximately 500 ll in PBS with 2% FBS. For ErbB3 and ErbB4
analysis, cells were incubated on ice for 30 min with 5 lg primary
antibodies, washed with ice-cold PBS/FBS, and subsequently incu-
bated for 30 min on ice with R-PE-conjugated secondary antibodies
(1:50 (v/v)). Flow cytometry was performed using a FACScan ﬂow
cytometer (BD Biosciences).
2.6. Receptor phosphorylation and MAPK activation experiments
Cells were harvested, washed with PBS, and serum-starved overnight
in complete Schneider’s medium supplemented with 0.5% FBS (star-
vation medium). Cells were then stimulated on ice (for receptor
phosphorylation) or at room temperature (for MAP kinase (MAPK)
phosphorylation studies) for 10 min with 100 ng/ml EGF (Intergen,
Purchase, NY) or human NRG1-b1 EGF domain (R&D Systems,
Minneapolis, MN) or were left untreated. The cells were washed with
ice-cold PBS and lysed in RIPA buﬀer (25 mM Tris–HCl, pH 7.5, 150
mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1
mM PMSF, 1 lg/ml leupeptin, 1 lg/ml aprotinin, 25 mM NaF, 5 mM
Na2MoO4, and 0.2 mM Na3VO4), and clariﬁed by centrifugation at
14 000 rpm for 10 min at 4 C. Boiled samples of equal protein levels
were then subjected to Western blotting analysis with the indicated
antibodies, followed by horseradish peroxidase-conjugated secondary
antibodies, and were detected using chemiluminescence.3. Results
Since the tyrosine kinase domain of ErbB3 appears to be
catalytically impaired or inactive [5–7], ligand-induced dimer-
ization of this receptor cannot be followed by directly ana-
lyzing its autophosphosphorylation. To circumvent this
problem, we generated a chimera with the extracellular region
plus transmembrane domain of ErbB3 fused to the cytoplas-
mic region of EGFR. This chimera will have the NRG-binding
properties of ErbB3, yet its intracellular region should be ca-
pable of dimerization-dependent kinase activation as seen with
EGFR. If NRG-binding does induce dimerization of the
ErbB3 extracellular region in a cellular context, this should be
evidenced by ligand-induced autophosphorylation of the
ErbB3/ErbB1 chimera and resulting MAPK activation. As a
positive control, we also generated a chimera in which the
extracellular region is instead derived from ErbB4. Previouswork has shown that the extracellular region of ErbB4 oligo-
merizes readily upon NRG binding [15], so the ErbB4/ErbB1
chimera should certainly show NRG-regulated autophospho-
rylation and activation. A schematic representation of the
ErbB receptors and the chimerae is shown in Fig. 1.
3.1. Signaling by human ErbB receptors in Drosophila
Schneider-2 cells
We used the Drosophila melanogaster Schneider-2 (S2)
cell-line as a null background for mammalian ErbB proteins.
Insect cell-lines have previously been used as cellular back-
grounds for a number of studies of the human ErbB receptors
[7,16,21–23].
We ﬁrst tested the utility of S2 cells by generating cells that
stably overexpress human ErbB1 or ErbB2. As shown in
Fig. 2, human ErbB1 expressed in S2 cells was tyrosine auto-
phosphorylated in response to EGF (but not NRG) treatment.
In addition, robust EGF-induced activation (phosphoryla-
tion) of Drosophila rolled/MAPK could be detected by im-
munoblotting with anti-phospho-MAPK antibodies. These
responses were EGF-speciﬁc, and were only found in ErbB1-
expressing S2 cells. No similar responses were detected upon
EGF or NRG treatment of parental S2 cells or cells expressing
human ErbB2.
3.2. NRG eﬃciently activates an ErbB4/ErbB1 chimera, but not
an ErbB3/ErbB1 chimera
Having established that human ErbB1 can signal in S2 cells,
we next generated cell-lines that stably express either the
ErbB3/ErbB1 or ErbB4/ErbB1 chimera depicted in Fig. 1. We
veriﬁed that that both chimerae were expressed at the cell
surface using ﬂow cytometry (Fig. 3), indicating that our chi-
meric receptors are correctly folded and processed – so that
diﬀerential accessibility to extracellular ligand can be ruled out
in interpreting any diﬀerences in their signaling. Comparative
studies of human breast cancer cell lines with reported num-
bers of NRG-binding sites [24] suggested that our chimerae are
expressed at 104–105 copies per cell, with the ErbB3/ErbB1
chimera expressed at 2–5 fold higher levels than the ErbB4/
ErbB1 chimera.
We analyzed the ability of NRG to stimulate autophos-
phorylation of the ErbB3/ErbB1 and ErbB4/ErbB1 chimerae
Fig. 4. Analysis of signaling by ErbB3/ErbB1 and ErbB4/ErbB1 chi-
merae in S2 cells. (A) S2 cells stably expressing the ErbB3/ErbB1 and
ErbB4/ErbB1 chimera were left unstimulated or treated with NRG on
ice. Receptor autophosphorylation was analyzed by immunoblotting
with anti-phosphotyrosine (a-P-Tyr) antibody (upper blot). An arrow
highlights the bands corresponding to the human ErbB receptor chi-
merae. Chimera expression was conﬁrmed by Western blotting with an
antibody speciﬁc for the ErbB1 intracellular domain (a-ErbB1 endo)
antibody (lower blot). (B) Stable cell pools expressing ErbB3/ErbB1 or
ErbB4/ErbB1 were treated for 10 min at room-temperature with no
growth factor ()) or with NRG (+). Upper blot: detection of activated
MAPK (a-P-MAPK). Lower blot: detection of total MAPK loaded
(a-MAPK).
Fig. 3. Cell-surface expression of ErbB3/ErbB1 and ErbB4/ErbB1
chimerae. Expression of the ErbB3/ErbB1 (A) and ErbB4/ErbB1
(B) chimerae on the cell surface, analyzed by ﬂow cytometry. The solid
gray traces (with peaks shaded gray) represent data from parental S2
cells treated with the primary and secondary antibodies, while the
black traces represent data from the stable cell-lines analyzed in the
same fashion. The marked right-shifts in each case demonstrate that
both chimerae are expressed appropriately at the cell surface. 10 000
cells were analyzed for each FACS analysis.
Fig. 2. Ligand-induced activation of human ErbB receptors in Dro-
sophila S2 cells. Receptor autophosphorylation and MAPK activation
were analyzed by immunoblotting whole-cell lysates from parental,
ErbB1-expressing, and ErbB2-expressing S2 cells after treatment with
human EGF or NRG. The primary antibodies used for Western
blotting are marked at left, and recognize phospho-tyrosine (a-P-Tyr)
(top blot), phosphorylated MAPK (a-P-MAPK) (middle blot), and
pan-MAPK (a-MAPK) (lower blot). The arrow at right in the top blot
marks the size of the exogenous ErbB receptor bands to distinguish
from endogenous Drosophila phospho-tyrosine containing proteins.
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NRG-induced autophosphorylation was detected in cells ex-
pressing the ErbB4/ErbB1 chimera, but no response was ob-
served with the ErbB3/ErbB1 chimera. Similarly, NRG
promoted strong MAPK phosphorylation in S2 cells express-
ing the ErbB4/ErbB1 chimera but not those expressing ErbB3/
ErbB1 (Fig. 4B). Thus, the ErbB3/ErbB1 chimera is not sen-
sitive to ligand stimulation despite that fact that it is well ex-
pressed at the cell surface (Fig. 3A), and that an identically
designed ErbB4/ErbB1 chimera signals robustly. Together
with our inability to detect dimers of the ErbB3 extracellular
region in biophysical studies [15], these results argue that
ErbB3 does not homodimerize when it binds NRG.
3.3. The ErbB3/ErbB1 chimera forms a functional heteromeric
NRG receptor with ErbB2
To rule out the possibility that the ErbB3/ErbB1 chimera is
non-functional for some reason not controlled for in our in-
vestigation, we asked whether it could form an active signaling
complex with human ErbB2. As mentioned in Section 1, li-
gand-induced active ErbB3/ErbB2 heterodimers are thought to
be potently mitogenic (and oncogenic). Alone, neither ErbB2
nor ErbB3 can activate signaling cascades upon NRG-stimu-
lation. However, coexpression of ErbB2 with ErbB3 generates
Fig. 5. Transient expression of ErbB2 reconstitutes NRG signaling in
S2 cells expressing the ErbB3/ErbB1 chimera. (A) S2 cells expressing
the ErbB3/ErbB1 chimera were transiently transfected with human
ErbB2 and were stimulated with NRG. Immunoblotting of whole-cell
lysates was performed with an anti-ErbB2 antibody (upper blot) anti-
phosphotyrosine (middle blot), and chimera expression (lower blot)
was detected with an anti-ErbB1 endodomain-speciﬁc antibody (a-
ErbB1 endo). (B) MAPK activation was analyzed by immunoblotting
of whole-cell lysates of ErbB3/ErbB1-expressing cells transiently
transfected with control or ErbB2 vectors. Upper blot: ErbB2 ex-
pression (a-ErbB2). Middle blot: activated MAPK (a-P-MAPK).
Lower blot: total MAPK loaded (a-MAPK).
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tion results primarily from extracellular interactions, we an-
ticipate that coexpression of ErbB2 with the ErbB3/ErbB1
chimera in S2 cells should also reconstitute NRG signaling.
We transiently transfected ErbB3/ErbB1-expressing S2 cells
with a plasmid that drives expression of full-length human
ErbB2. As shown in Fig. 5, although transient overexpression
of ErbB2 in these cells resulted in high levels of basal auto-
phosphorylation as described by others [26,27], a slight NRG-
induced enhancement of receptor autophosphorylation can be
discerned in the cells co-expressing ErbB2 and the ErbB3/
ErbB1 chimera. More convincingly, Fig. 5B shows that,
whereas NRG does not promote MAPK activation in parental
or ErbB2-expressing S2 cells (see Fig. 2) or the ErbB3/ErbB1
chimera alone, it does induce a robust increase in phospho-
MAPK levels when both proteins are expressed. These results
argue that the ErbB3/ErbB1 chimera can respond to NRG.
However, like wild-type ErbB3, it is only competent to signal
when expressed alongside another ErbB receptor with which it
can form heteromeric complexes. Interestingly, this appears to
be a property of ErbB3 whether its kinase domain is active (as
in our ErbB3/ErbB1 chimera) or impaired (as in wild-type
ErbB3). We therefore suggest that the unusual signaling
properties of ErbB3 arise less from its reported inability to
function as a tyrosine kinase than from its inability to form
ligand-induced homodimers.4. Discussion
A key question in ErbB receptor signaling is whether ligand
binding causes ErbB2 and ErbB3 to form heterodimers or
larger oligomers. If ErbB3 is kinase-inactive, and therefore
cannot phosphorylate ErbB2 directly, it is diﬃcult to see how
NRG could activate ErbB2 in the context of an ErbB2/ErbB3heterodimer. This consideration has led to the suggestion that
higher order hetero-oligomers must form [3,15,28], perhaps
nucleated by NRG-induced ErbB3 homodimerization, allow-
ing ErbB2 molecules to phosphorylate one another. Here, we
provide evidence suggesting that NRG does not induce ErbB3
homodimerization at the cell surface, supporting previous
studies employing isolated extracellular domains [14–17].
These ﬁndings argue against the hypothesis that NRG induces
large ErbB2/ErbB3 hetero-oligomers, and together with recent
structural studies [29] are more consistent with the possibility
that ErbB3 does directly activate ErbB2 in the context of
NRG-induced ErbB2/ErbB3 heterodimers.
How might ErbB3 trans-activate ErbB2 in such a heterodi-
mer? One possibility is that it does possess signiﬁcant (but low
level) kinase activity, and can trans-phosphorylate ErbB2 in
the context of a heterodimer. The initial suggestion that the
ErbB3 kinase domain is impaired was sequence-based [30,31],
and was supported by subsequent studies of the intact protein
[5–7] and its isolated kinase domain [6] (although none con-
clusively demonstrated an absence of activity). Guy et al. [5]
reported that the tyrosine kinase activity of full-length insect
cell-expressed ErbB3 is at least 100-fold weaker than that for
ErbB1 or ErbB2. ErbB3 autophosphorylation and substrate
phosphorylation was readily detectable in these studies, but its
insensitivity to NRG treatment led to the interpretation that
ErbB3 alone was not responsible. However, if NRG does not
promote ErbB3 homodimerization – as our studies and pre-
vious biophysical analyses suggest – then such NRG activation
would not be expected. Thus, a possible interpretation of
earlier phosphorylation studies is that ErbB3 does in fact have
a low (but nonetheless detectable) level of kinase activity, but
that it is not activated (through homodimerization) by NRG
binding to the extracellular region. Caution should, therefore,
be exercised in assuming that ErbB3 is truly ‘kinase-dead’.
Indeed, consistent with a requirement for ErbB3 kinase ac-
tivity, Wallasch et al. [26] found that mutation of a critical
lysine in the ATP binding site of ErbB3 signiﬁcantly reduces
the extent of NRG-induced ErbB2 phosphorylation in cells
expressing both ErbB2 and the mutated (or wild-type) ErbB3.
These ﬁndings are clearly consistent with the possibility that
ErbB3 directly phosphorylates ErbB2 in the context of a
NRG-induced ErbB2/ErbB3 heterodimer.
It should be noted that our ﬁndings with the ErbB3/ErbB1
chimera contradict two previous reports. In chemical cross-
linking studies, Tzahar et al. [20] failed to detect NRG-induced
dimerization of the ErbB3 extracellular region, but could detect
cross-linked dimers when the ErbB3 extracellular region was
membrane anchored by a transmembrane domain or lipid an-
chor. Since ErbB3 was only detected in these studies by aﬃnity
labeling with 125I labeled NRG, it is not clear whether the
observed crosslinked oligomeric species are enhanced by ligand
binding, or are constitutive (as suggested in other studies of
ErbB3 [16,17]). Alimandi et al. [32] also generated an ErbB3/
ErbB1 chimera with the ErbB3 extracellular region fused to the
transmembrane and intracellular domains of ErbB1. This chi-
mera did appear to become phosphorylated following NRG
treatment in 32D cells, by contrast with our ﬁndings in S2 cells
[32]. It is unlikely that the diﬀerent origin of the transmembrane
domain in our studies (where it was ErbB3-derived) and those
of Alimandi et al. (where it was ErbB1-derived) could explain
this discrepancy. The cellular background therefore seems a
more likely origin of the diﬀerence. Although the murine 32D
336 M.B. Berger et al. / FEBS Letters 569 (2004) 332–336cell-line used by Alimandi and colleagues has been reported to
be ErbB receptor null [11], it may contain endogenous ErbB
receptors that are not detectable, but nonetheless interact
productively with the exogenous chimera. Indeed, such en-
dogenous receptors could also explain the surprising observa-
tion that in 32D cells (but not BaF3 cells) co-expressed ErbB2
and ErbB3 (or the ErbB3/ErbB1 chimera) appear to respond to
EGF and betacellulin (despite the fact that neither receptor
binds these ligands) [32–35].
Excepting these caveats, we argue that NRG does not induce
homodimerization of intact ErbB3 or its isolated extracellular
region. Some evidence was previously presented for weak
NRG-induced hetero-oligomerization of the ErbB2 and ErbB3
extracellular domains [15] (although others have not seen this
[14]), and our data suggest that NRG induces ErbB3/ErbB2
heterodimerization in the absence of ErbB3 homodimeriza-
tion. Assuming a simple heterodimerization mechanism based
on recent structural studies [29], it can be argued that ErbB2
will be activated much more eﬃciently by ligand-bound ErbB3
than by ligand-bound ErbB4 or ErbB1. Whereas ligand-bound
ErbB1 or ErbB4 may prefer to form homodimers than to
heterodimerize with, and activate, ErbB2, there is no such
homomeric alternative for NRG-bound ErbB3. Given the
mitogenic potency of activated ErbB2, this lack of competition
from homodimerization may provide part of the reason why
the ErbB2/ErbB3 combination appears to be particularly po-
tent in propagating mitogenic signals in tissue culture systems,
and has also been identiﬁed in a wide array of human tumors
[2,8,12,36].
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